期刊文献+

药物诱发非酒精性脂肪性肝病患者肝损伤的机制

Mechanism of drug-induced liver injury in patients with non-alcoholic fatty liver disease
下载PDF
导出
摘要 肝脏通过代谢、转运和清除异物等功能在降低药物毒性方面起着至关重要的作用。药物性肝损伤(drug-induced liver injury,DILI)是西方国家急性肝衰竭的主要病因,由于久坐的生活方式和摄入热量过度,我国还面临着肥胖和非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的困扰。脂肪肝可增大各种疾病(如糖尿病、心血管疾病和不孕不育症等)的风险,是威胁公众健康的又一主要问题。为了治疗相关疾病,NAFLD患者平均使用的药量远高于非NAFLD患者,增大了患DILI的风险。希望临床医生重视该特殊人群用药的安全性。 Liver plays a crucial role in eliminating the toxicity of drugs due to its function in the metabolism, transport, and clearance of foreign substances. In Western countries, drug-induced liver injury (DILI) is the major cause of acute liver failure. Moreover, we are also facing the problems of obesity and non-alcoholic fatty liver disease (NAFLD) in China, due to the sedentary lifestyle and calorie overeonsumption. NAFLD poses a major public health problem since it primarily enhances the risk of various ill- nesses, such as diabetes, cardiovascular disease and infertility, etc. For the treatment of related diseases, NAFLD patients are con- suming more drugs than non-NAFLD individuals, which increases the risk of DiLL Therefore, it is hoped that clinicians should pay attention to safety issues of drug use in NAFLD patients.
作者 王慧 王炳元
出处 《传染病信息》 2013年第5期266-267,共2页 Infectious Disease Information
基金 辽宁省科技厅科技攻关项目(2011225015)
关键词 脂肪肝 药物性肝损伤 病理过程 fatty liver drug-induced liver injury pathologic processes
  • 相关文献

参考文献15

  • 1Begriche K,Massart J,Robin MA,et al.Drug-induced toxicity on mitochondria and lipid metabolism:mechanistic diversity and deleterious consequences for the liver[J].J Hepatol,2011,54(4):773-794.
  • 2Aubert J,Begriche K,Knockaert L,et al.Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease:mechanisms and pathophysiological role[J].Clin Res Hepatol Gastroenterol,2011,35(10):630-637.
  • 3王菲,郑娉娉,王炳元,王柏芳,马力,丁媛媛,李金萍,王颖.酒精性肝硬化患者的临床特征[J].传染病信息,2011,24(5):271-274. 被引量:19
  • 4Leung TM,Nieto N.CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease[J].J Hepatol,2013,58(2):395-398.
  • 5Ito Y,Sasaki M,Funaki Y,et al.Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury[J].J Clin Biochem Nutr,2013,53(1):55-59.
  • 6Nagata K,Suzuki H,Sakaguchi S.Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis[J].J Toxicol Sci,2007,32(5):453-468.
  • 7Sookoian S,Casta(n)o GO,Burgue(n)o AL,et al.The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease[J].Pharmacogenet Genomics,2010,20(1):1-8.
  • 8He J,Lee JH,Febbraio M,et al.The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease[J].Exp Biol Med (Maywood),2011,236(10):1116-1121.
  • 9Begriche K,Massart J,Robin MA,et al.Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease[EB/OL].[2013-07-12].http://www.ncbi.nlm.nih.gov/pubmed/?term=Mitochondrial+adaptations+and+dysfunctions+in+nonalcoholic+fatty+liver+disease.
  • 10刘新胜,臧红,游绍莉,柳芳芳,申力军,万志红,刘鸿凌,辛绍杰.288例药物性肝损害的临床诊断及病理学分析[J].传染病信息,2013,26(3):168-170. 被引量:7

二级参考文献25

  • 1中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].传染病信息,2005,18(z1):1-12. 被引量:467
  • 2中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):49-53. 被引量:385
  • 3Danan G, Benichou C. Causality assessment of adverse reactions todrugs-I. A novel method based on the conclusions of internationalconsensus meeting: application to drug-induced liver injuries[J].J Clin Epidemiol, 1993,46(11):1323-1330.
  • 4Benichou C. Criteria of drug-induced liver disorders. Report of aninternational consensus meeting[J]. J Hepatol, 1990, 11(2):272-276.
  • 5Ursem CJ, Kruhlak NL, Contrera JF, et al. Identification of struc-ture-activity relationships for adverse effects of pharmaceuticals inhumans. Part A: use of FDA post-market reports to create a da-ta-base of hepatobiliary and urinary tract toxicides [J]. Regul Tox-icol Pharmacol, 2009, 54(1):1-22.
  • 6Suk KT, Kim DJ. Drug-induced liver injury: present and future[J].Clin Mol Hepatol, 2012, 18(3):249-257.
  • 7Maria VA, Victorino RM. Development and validation of a clinicalscale for the di^nosis of drug-induced hepatitis [ J ]. Hepatology,1997, 26(3):664-669.
  • 8Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287Japanese cases of drug induced liver injury by the diagnostic scaleof the International Consensus Meeting[J]. Hepatol Res, 2003, 27(3):192-195.
  • 9Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute id-iosyncratic drug-induced liver injury: long-term follow-up in a hepa-totoxicity registry[J]. Hepatology, 2006, 44(6):1581-1588.
  • 10BjOmsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-inducedautoimmune hepatitis: clinical characteristics and prognosis[J]. He-patology, 2010, 51(6):2040-2048.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部